Association between the vascular endothelial growth factor single nucleotide polymorphisms and diabetic retinopathy risk: A meta-analysis

Journal of Diabetes

Volumn 9, Issue 8, 2017, Pages 738-753

  Xie, Xiu Jing ^a   Yang, Yun Mei ^a   Jiang, Jiu Kun ^b   Lu, Yuan Qiang ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

diabetic retinopathy; single nucleotide polymorphism; vascular endothelial growth factor

Indexed keywords

VASCULOTROPIN; VASCULOTROPIN A;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ALLELE; ARTICLE; DIABETIC RETINOPATHY; DOMINANT GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; HETEROZYGOTE; HOMOZYGOTE; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROMOTER REGION; RECESSIVE GENE; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; VEGF GENE; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS;

DIABETIC RETINOPATHY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 85002904707     PISSN: 17530393     EISSN: 17530407     Source Type: Journal    
DOI: 10.1111/1753-0407.12480     Document Type: Article

References (45)

1. Scalone L, Cesana G, Furneri G, et al. Burden of diabetes mellitus estimated with a longitudinal population-based study using administrative databases. PLoS One. 2014; 9: E113741.
2. Dall TM, Yang W, Halder P et al. The economic burden of elevated blood glucose levels in 2012: Diagnosed and undiagnosed diabetes, gestational diabetes mellitus, and prediabetes. Diabetes Care. 2014; 37: 3172–3179.
3. Agarwal A, Soliman MK, Sepah YJ, Do DV, Nguyen QD. Diabetic retinopathy: Variations in patient therapeutic outcomes and pharmacogenomics. Pharmgenomics Pers Med. 2014; 7: 399–409.
4. Jha JC, Jandeleit-Dahm KA, Cooper ME. New insights into the use of biomarkers of diabetic nephropathy. Adv Chronic Kidney Dis. 2014; 21: 318–326.
5. Han L, Zhang L, Xing W et al. The associations between VEGF gene polymorphisms and diabetic retinopathy susceptibility: A meta-analysis of 11 case–control studies. J Diabetes Res. 2014; 2014: 805801.
6. El-Shazly SF, El-Bradey MH, Tameesh MK. Vascular endothelial growth factor gene polymorphism prevalence in patients with diabetic macular oedema and its correlation with anti-vascular endothelial growth factor treatment outcomes. Clin Exp Ophthalmol. 2014; 42: 369–378.
7. Fan X, Wu Q, Li Y et al. Association of polymorphisms in the vascular endothelial growth factor gene and its serum levels with diabetic retinopathy in Chinese patients with type 2 diabetes: A cross-sectional study. Chin Med J (Engl). 2014; 12: 651–657.
8. Yang X, Deng Y, Gu H et al. Candidate gene association study for diabetic retinopathy in Chinese patients with type 2 diabetes. Mol Vis. 2014; 20: 200–214.
9. Yuan Y, Wen Z, Guan Y et al. The relationships between type 2 diabetic retinopathy and VEGF-634G/ C and VEGF-460C/T polymorphisms in Han Chinese subjects. J Diabetes Complicat. 2014; 28: 785–790.
10. Bonnefond A, Saulnier PJ, Stathopoulou MG, et al. What is the contribution of two genetic variants regulating VEGF levels to type 2 diabetes risk and to microvascular complications? PLoS One. 2013; 8:e55921.
11. International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature. 2004; 431: 931–945.
12. Nikzamir A, Esteghamati A, Hammedian AA, Mahmoudi T. The role of vascular endothelial growth factor +405 G/C polymorphism and albuminuria in patients with type 2 diabetes mellitus. Mol Biol Rep. 2012; 39: 881–886.
13. Sun L, Yuan Q, Cao N et al. VEGF genetic polymorphisms may contribute to the risk of diabetic nephropathy in patients with diabetes mellitus: A meta-analysis. Scientific World Journal. 2014; 2014: 624573.
14. Wang H, Cheng JW, Zhu LS et al. Meta-analysis of association between the −2578 C/A polymorphism of the vascular endothelial growth factor and retinopathy in type 2 diabetes in Asians and Caucasians. Ophthalmic Res. 2014; 52: 1–8.
15. Qiu M, Xiong W, Liao H, Li F. VEGF –634G > C polymorphism and diabetic retinopathy risk: A meta-analysis. Gene. 2013; 518: 310–315.
16. Lu Y, Ge Y, Shi Y, Yin J, Huang Z. Two polymorphisms (rs699947, rs2010963) in the VEGFA gene and diabetic retinopathy: An updated meta-analysis. BMC Ophthalmol. 2013; 13: 56.
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Statistics in medicine. 2002; 21: 1539–1558.
18. DerSimonian R, Laird N. Meta-analysis in clinical trials. Controlled clinical trials. 1986; 7: 177–188.
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. Journal of the National Cancer Institute. 1959; 22: 719–748.
20. Awata T, Inoue K, Kurihara S et al. A common polymorphism in the 5′-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002; 51: 1635–1639.
21. Awata T, Kurihara S, Takata N et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem Biophys Res Commun. 2005; 333: 679–685.
22. Bleda S, De Haro J, Varela C, Esparza L, Ferruelo A, Acin F. Vascular endothelial growth factor polymorphisms are involved in the late vascular complications in Type II diabetic patients. Diab Vasc Dis Res. 2012; 9: 68–74.
23. Buraczynska M, Ksiazek P, Baranowicz-Gaszczyk I, Jozwiak L. Association of the VEGF gene polymorphism with diabetic retinopathy in type 2 diabetes patients. Nephrol Dial Transplant. 2007; 22: 827–832.
24. Chun MY, Hwang HS, Cho HY et al. Association of vascular endothelial growth factor polymorphisms with nonproliferative and proliferative diabetic retinopathy. J Clin Endocrinol Metab. 2010; 95: 3547–3551.
25. Kangas-Kontio T, Vavuli S, Kakko SJ et al. Polymorphism of the manganese superoxide dismutase gene but not of vascular endothelial growth factor gene is a risk factor for diabetic retinopathy. Br J Ophthalmol. 2009; 93: 1401–1406.
26. Nakamura S, Iwasaki N, Funatsu H et al. Impact of variants in the VEGF gene on progression of proliferative diabetic retinopathy. Graefes Arch ClinExpOphthalmol. 2009; 247: 21–26.
27. Petrovic MG, Korosec P, Kosnik M et al. Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy. Mol Vis. 2008; 14: 1382–1387.
28. Uthra S, Raman R, Mukesh BN et al. Association of VEGF gene polymorphisms with diabetic retinopathy in a south Indian cohort. Ophthalmic Genet. 2008; 29: 11–15.
29. Paine SK, Basu A, Mondal LK et al. Association of vascular endothelial growth factor, transforming growth factor beta, and interferon gamma gene polymorphisms with proliferative diabetic retinopathy in patients with type 2 diabetes. Mol Vis. 2012; 18: 2749–2757.
30. Abhary S, Burdon KP, Gupta A et al. Common sequence variation in the VEGFA gene predicts risk of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2009; 50: 5552–5558.
31. Kim HW, Ko GJ, Kang YS et al. Role of the VEGF 936 C/T polymorphism in diabetic microvascular complications in type 2 diabetic patients. Nephrology (Carlton). 2009; 14: 681–688.
32. Jorgensen AL, Williamson PR. Methodological quality of pharmacogenetic studies: Issues of concern. Stat Med. 2008; 27: 6547–6569.
33. Errera FI, Canani LH, Silva ME et al. Functional vascular endothelial growth factor –634G > C SNP is associated with proliferative diabetic retinopathy: A case–control study in a Brazilian population of European ancestry. Diabetes Care. 2007; 30: 275–279.
34. Feghhi M, Nikzamir A, Esteghamati A et al. Relationship of vascular endothelial growth factor (VEGF) +405 G/C polymorphism and proliferative retinopathy in patients with type 2 diabetes. Transl Res. 2011; 158: 85–91.
35. Suganthalakshmi B, Anand R, Kim R et al. Association of VEGF and eNOS gene polymorphisms in type 2 diabetic retinopathy. Mol Vis. 2006; 12: 336–341.
36. Szaflik JP, Wysocki T, Kowalski M et al. An association between vascular endothelial growth factor gene promoter polymorphisms and diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2008; 246: 39–43.
37. Yang Y, Andresen BT, Yang K et al. Association of vascular endothelial growth factor –634C/G polymorphism and diabetic retinopathy in type 2 diabetic Han Chinese. Exp Biol Med (Maywood). 2010; 235: 1204–1211.
38. Ray D, Mishra M, Ralph S et al. Association of the VEGF gene with proliferative diabetic retinopathy but not proteinuria in diabetes. Diabetes. 2004; 53: 861–864.
39. Churchill AJ, Carter JG, Ramsden C et al. VEGF polymorphisms are associated with severity of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2008; 49: 3611–3616.
40. Vailati FB, Crispim D, Sortica DA et al. The C allele of –634G/C polymorphism in the VEGFA gene is associated with increased VEGFA gene expression in human retinal tissue. Invest Ophthalmol Vis Sci. 2012; 53: 6411–6415.
41. Omar AF, Silva PS, Sun JK. Genetics of diabetic retinopathy. Semin Ophthalmol. 2013; 28: 337–346.
42. Moradzadegan A, Vaisi-Raygani A, Nikzamir A, Rahimi Z. Angiotensin converting enzyme insertion/deletion (I/D) (rs4646994) and Vegf polymorphism (+405G/C; rs2010963) in type II diabetic patients: Association with the risk of coronary artery disease. J Renin Angiotensin Aldosterone Syst. 2015; 16: 672–680.
43. Hamedian AA, Esteghamati A, Noshad S et al. Vascular endothelial growth factor (VEGF) +405 C/G polymorphism is associated with essential hypertension in a population from Tehran of Iran. Mol Biol Rep. 2012; 39: 6213–6218.
44. Freathy RM, Weedon MN, Shields B et al. Functional variation in VEGF is not associated with type 2 diabetes in a United Kingdom Caucasian population. JOP. 2006; 7: 295–302.
45. Zeng Y, Dai F, Yang K, Tang Y, Xu M, Zhou Y. Association between a vascular endothelial growth factor gene polymorphism (rs2146323) and diabetic retinopathy: A meta-analysis. BMC Ophthalmol. 2015; 15: 163.